McClung Barbara G's Form 4 filing
Caribou Biosciences, Inc. (CRBU) · filed Feb 21, 2025
- Accession no.
- 0001231321-25-000003
- Filed
- Feb 21, 2025
- Trade date
- Feb 20-21, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.81K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McClung Barbara GCIK 0001231321 | Officer (Chief Legal Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 20, 2025 | Common Stock | AGrant or awardAcquired | +37,500 | $0.00 | $0 | 447,066 | Direct | |
| Feb 21, 2025 | Common Stock | SSaleDisposed | −3,564 | $1.35F3 | −$4,811.4 | 443,502 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 20, 2025 | Common Stock | AGrant or awardAcquired | +170,000 | $0.00 | $0 | 170,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades on 2/21/2025 at prices ranging from $1.32 to $1.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the specified range.
Referenced by the price of 1 transaction in Table I.